Everolimus-Eluting Stent for Bifurcation Coronary Lesions: Comparison of Simple Versus Complex Techniques

NCT00916695 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2009-07-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the treatment of true bifurcation lesions with the XIENCE V stent using the simple strategy (stent in main vessel and provisional T-stenting in the side branch) compared to the complex strategy (stent in main vessel and T-stenting in the side branch).

Conditions

Interventions

DEVICE

Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.

Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique. Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique.

Sponsors & Collaborators

  • Spanish Society of Cardiology

    lead OTHER

Principal Investigators

  • Federico Gimeno, MD · Hospital Clinico Universitario Valladolid

  • Bruno Garcia, MD · Hospital Valle de Hebron. Barcelona

  • Ramiro Trillo, MD · Hospital Clínico Santiago

  • Jose Moreu, MD · Hospital Virgen de la Salud

  • Javier Goicolea, MD · Hospital Puerta de Hierro, Madrid

  • Raul Moreno, MD · Hospital Universitario La Paz

  • Jose F Diaz, MD · Hospital Juan Ramon Jimenez. Huelva

  • Jose M Hernandez, MD · Hospital Clinico de Malaga

  • Ramon Lopez-Palop, MD · Hospital San Juan. Alicante

  • Mariano Valdes, MD · Hospital Universitario Virgen de la Arrixaca

  • Pascual Bordes, MD · Hospital Universitario. Alicante

  • Jose R Rumoroso, MD · Hospital Galdakao. Vizcaya

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00916695 on ClinicalTrials.gov